<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580047</url>
  </required_header>
  <id_info>
    <org_study_id>437-02-FB</org_study_id>
    <nct_id>NCT00580047</nct_id>
  </id_info>
  <brief_title>Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants</brief_title>
  <official_title>Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to look at the effect of different bone treatment plans on bone loss
      after kidney or kidney/pancreas transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims are to determine baseline bone mineral density (BMD) in kidney and kidney/pancreas
      transplant patients who will be randomized to weekly alendronate, annual zoledronic acid
      infusions or placebo (calcium with Vitamin D). These patients will be followed for two years
      with annual bone density testing as well as biochemical markers. A secondary aim is to
      evaluate the compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Posterior Anterior (PA) Spine Bone Density From Baseline to 24 Months Post Transplant</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage Change in Posterior Anterior (PA) spine bone density from baseline to 24 months post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance With Zoledronic Acid, Alendronate and/or Calcium/Vitamin D Supplementation</measure>
    <time_frame>24 months</time_frame>
    <description>Compare compliance where a study coordinator interviewed patients as to how often they missed the once a week oral alendronate, missed taking calcium and vitamin D supplementation, or missed the once a year IV Reclast.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic Acid 4mg intravenously once a year for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate 70mg orally once a week for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>4mg IV Annually</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Calcium with vitamin D</intervention_name>
    <description>1200 mg Calcium with 800 International Units of vitamin D</description>
    <arm_group_label>3</arm_group_label>
    <other_name>calcium citrate</other_name>
    <other_name>calcium carbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>70mg weekly</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Transplant patients who have had a kidney or kidney/pancreas transplant in the last
             150 days with adequate kidney function as defined by a calculated creatine clearance
             of 35ml/min or more and serum creatinine less than 3.0

        Exclusion Criteria:

          -  Dual X-ray Absorptiometry (DXA) T-score at the spine or hip of -3 or lower

          -  History of more than one vertebral or non-vertebral fracture in the past two years

          -  Abnormalities of the esophagus which delay esophageal emptying

          -  Inability to stay upright for 30 minutes

          -  Pregnant, nursing women or women not using an effective form of birth control

          -  Hypocalcemia

          -  Hypercalcemia

          -  Calculated creatinine clearance of &lt;35 ml/min or serum creatinine &gt; 3.0

          -  Patients already treated with bisphosphonates within the past one year

          -  Patients unable to undergo DXA

          -  Patients with cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wang J, Yao M, Xu JH, Shu B, Wang YJ, Cui XJ. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials. Osteoporos Int. 2016 May;27(5):1683-90. doi: 10.1007/s00198-015-3465-7. Epub 2016 Jan 5. Review.</citation>
    <PMID>26733377</PMID>
  </reference>
  <reference>
    <citation>Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012 Dec;97(12):4481-90. doi: 10.1210/jc.2012-2804. Epub 2012 Sep 28.</citation>
    <PMID>23024190</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>January 18, 2016</results_first_submitted>
  <results_first_submitted_qc>March 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2018</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Lynn Mack, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>bone density</keyword>
  <keyword>osteopenia</keyword>
  <keyword>transplant</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>alendronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients from the Kidney Pancreas Transplant clinic at the University of Nebraska Medical Center who underwent a kidney, pancreas, or kidney-pancreas transplant from 2003 to 2009 were invited to participate.</recruitment_details>
      <pre_assignment_details>Participants were recruited during the transplant hospitalization or within 30 days of transplantation. They were excluded if they had an esophageal abnormality, bone density T-score of -3 or lower, fracture in the last 2 years, Cr Cl of 35 or less, inability to sit upright for 30 minutes after swallowing a medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Bisphosphonate Post Transplantation</title>
          <description>Zoledronic Acid 4mg
Zoledronic Acid: 4mg IV Annually</description>
        </group>
        <group group_id="P2">
          <title>Oral Bisphosphonate Post Transplantation</title>
          <description>Alendronate 70mg
Alendronate: 70mg weekly</description>
        </group>
        <group group_id="P3">
          <title>Placebo Group Post Transplantation</title>
          <description>Calcium 1200mg Vitamin D 800IU
calcium and Vitamin D: 1200 mg Calcium 800 International Units Vitamin D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Men and women post kidney or kidney pancreas transplantation</population>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Bisphosphonate Post Transplantation</title>
          <description>Zoledronic Acid 4mg
Zoledronic Acid: 4mg IV Annually</description>
        </group>
        <group group_id="B2">
          <title>Oral Bisphosphonate Post Tranpslantation</title>
          <description>Alendronate 70mg
Alendronate: 70mg weekly</description>
        </group>
        <group group_id="B3">
          <title>Placebo Post Transplantation</title>
          <description>Calcium 1200mg Vitamin D 800IU
calcium and Vitamin D: 1200 mg Calcium 800 International Units Vitamin D</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="11"/>
                    <measurement group_id="B2" value="50" spread="15"/>
                    <measurement group_id="B3" value="46" spread="12"/>
                    <measurement group_id="B4" value="47" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spine bone density</title>
          <description>mean spine bone density in g/cm2</description>
          <units>grams/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="0.03"/>
                    <measurement group_id="B2" value="1.28" spread="0.046"/>
                    <measurement group_id="B3" value="1.12" spread="0.05"/>
                    <measurement group_id="B4" value="1.3" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Posterior Anterior (PA) Spine Bone Density From Baseline to 24 Months Post Transplant</title>
        <description>Percentage Change in Posterior Anterior (PA) spine bone density from baseline to 24 months post transplant</description>
        <time_frame>24 months</time_frame>
        <population>Percentage change in spine bone density from baseline to 24 months</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Bisphosphonate Post Transplantation</title>
            <description>Zoledronic Acid 4mg
Zoledronic Acid: 4mg IV Annually
8% increase</description>
          </group>
          <group group_id="O2">
            <title>Oral Bisphosphonate Post Transplantation</title>
            <description>Alendronate 70mg
Alendronate: 70mg weekly
8% increase</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group Post Transplantation</title>
            <description>Calcium 1200mg Vitamin D 800IU
calcium and Vitamin D: 1200 mg Calcium 800 International Units Vitamin D
8% increase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Posterior Anterior (PA) Spine Bone Density From Baseline to 24 Months Post Transplant</title>
          <description>Percentage Change in Posterior Anterior (PA) spine bone density from baseline to 24 months post transplant</description>
          <population>Percentage change in spine bone density from baseline to 24 months</population>
          <units>percentage of change of bone density</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="6.6"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance With Zoledronic Acid, Alendronate and/or Calcium/Vitamin D Supplementation</title>
        <description>Compare compliance where a study coordinator interviewed patients as to how often they missed the once a week oral alendronate, missed taking calcium and vitamin D supplementation, or missed the once a year IV Reclast.</description>
        <time_frame>24 months</time_frame>
        <population>Compliance in study arm</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Bisphosphonate Post Transplantation</title>
            <description>Zoledronic Acid 4mg
Zoledronic Acid: 4mg IV Annually
7.9% increase in spine bone density</description>
          </group>
          <group group_id="O2">
            <title>Oral Bisphosphonate Post Transplantation</title>
            <description>Alendronate 70mg
Alendronate: 70mg weekly
5.8% increase in spine bone density</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group Post Transplantation</title>
            <description>Calcium 1200mg Vitamin D 800IU
calcium and Vitamin D: 1200 mg Calcium 800 International Units Vitamin D
6.2% increase in spine bone density</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Zoledronic Acid, Alendronate and/or Calcium/Vitamin D Supplementation</title>
          <description>Compare compliance where a study coordinator interviewed patients as to how often they missed the once a week oral alendronate, missed taking calcium and vitamin D supplementation, or missed the once a year IV Reclast.</description>
          <population>Compliance in study arm</population>
          <units>percentage of compliance</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>The intervention groups were compared for compliance to either having annual IV zoledronic acid, taking weekly oral alendronate, and taking calcium/vitamin D supplementation.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>A study coordinator helped the patient complete a questionnaire of potential side effects/adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Bisphosphonate After Tranpslant</title>
          <description>Zoledronic Acid 4mg
Zoledronic Acid: 4mg IV Annually</description>
        </group>
        <group group_id="E2">
          <title>Oral Bisphosphonate After Transplant</title>
          <description>Alendronate 70mg
Alendronate: 70mg weekly</description>
        </group>
        <group group_id="E3">
          <title>Placebo After Transplant</title>
          <description>Calcium 1200mg Vitamin D 800IU
calcium and Vitamin D: 1200 mg Calcium 800 International Units Vitamin D</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample sizes and missing data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lynn Mack, Associate Professor</name_or_title>
      <organization>UNebraska</organization>
      <phone>4025596208</phone>
      <email>lmack@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

